von Hippel-Lindau disease tumor suppressor

BE0010427ProteinHumansVHL

Involved in the ubiquitination and subsequent proteasomal degradation via the von Hippel-Lindau ubiquitination complex (PubMed:10944113, PubMed:17981124, PubMed:19584355). It is acted on by 1 drug in DrugBank.

Gene name
VHL
UniProtKB entry
P40337Swiss-Prot
Cellular location
Cytoplasm
Residues / weight
213 residues · 24,153 Da
Also known as
Protein G7 · pVHL

Resolves to

Protein
UniProtP40337UniProt nameVHL_HUMAN
Gene
HGNCHGNC:12687NCBI Gene7428GeneCardsVHL
Pharmacology
IUPHAR/GtoPdb3204KEGGhsa:7428
Structure
PDB1LM8PDB1LQBPDB1VCB
Drugs

What you can answer from here — as of October 31, 2023

1DrugApproved to experimental, with action, bond type and pharmacological action
Sign in
13Clinical trialsTrials of drugs acting on it, by phase and status
Sign in
7GO termsFunction, process and component, as structured annotations
Sign in
2Pfam domainsDomain architecture mapped to Pfam families and clans
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which compounds in development act on von Hippel-Lindau disease tumor suppressor, and which indications are they being tested in?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In